Application of soluble IL-1 receptors and IL-1 receptor antagonist or IL-1β neutralizing antibodies inhibit acute myelogenous leukemia (AML) blast colony formation, which is reversed by IL-1β 29. Here, IL1B is linked to acute myeloid leukemia.